BSECompany Update22 Aug 2026 · 22 Aug 2026, 04:25 pm
Receipt of In Principle Approval
Parmax Pharma Ltd · 540359
✦ AI Summary▲ PositiveFundraise
Parmax Pharma Ltd has received in-principle approval from BSE Limited under Regulation 28(1) of the SEBI LODR Regulations for the issuance of equity shares and warrants on a preferential basis.
Analysis Scores
Earnings Impact6/10
Growth Catalyst8/10
Governance Concern1/10
Regulatory Risk5/10
Balance Sheet Risk2/10
Liquidity Impact9/10
Market Sentiment8/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Parmax Pharma Ltd - 540359 - Receipt Of ''In-Principle'' Approval Under Regulation 28(1) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For Issuance Of Equity Shares And Warrants On Preferential Basis
Attachments (1)
📄pdf
Download →
c2e3ffc2-4d93-4f17-94f9-7aa9f929b834.pdf
View document text
parmaX
Mfg. of : Bulk Drugs, Drug Intermediates & Speciality Chemicals PHARMA LTD.
Date: August 22, 2026
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai — 400 001
Scrip Code: 540359/PARMAX
SUBJECT: INTIMATION REGARDING RECEIPT OF'I N- PRINCIPLE’ APPURNDEOR RRVEEGGUUALLAATTLIIOONN
28(1) OF THE SEBI (LISTING OBLIGATIONSS AND DDIISSCCLLOO:S URE REQUIREMENTS) RREEGGUULLAATTIIOONNSS,, 22001155
FOR ISSUANCE OF EQUITY SHARES AND WAARRRRAANNTTSS ON PREFERENTIAL BASIS
Dear Sir/Madam,
Further to our intimation dated 8 June 2026, we wish to inform you that BSE Limited
(‘Exchange'/'BSE'), vide its letter no. LOD/PREF/DA/FIP/693/2026-27 dated August 21, 2026, has
granted its 'In-Principle' Approval under Regulation 28(1) of the SEBI LODR Regulations for the
proposed issuance of the following securities on a preferential basis to the allottes as per Notice of the
EGM:
@ 31,37,586 (Thirty One Lakh Thirty Seven Thousand Five Hundred and Eighty Six) Equity Shares
of face value of Rs. 10/- each at a price of not less than Rs.36.50/- (Rupees Thirty Six and Fifty
Paise only) per share; and
@ 21,45,145 (Twenty One Lakh Forty Five Thousand One Hundred and Forty Five) Warrants
convertible into an equal number of Equity Shares of face value of Rs. 10/- each at a price of
not less than Rs.36.50/- (Rupees Thirty Six and Fifty Paise only) per warrant.
The In-Principle approval is subject to necessary compliance under Applicable SEB! regulations.
This is for your information and records.
Kindly take the same on record.
Thanking you,
Yours faithfully,
Yiorabs.
For Parmax Pharma Limited
Umang Gosalia
DIN: 05153830
Managing Director
PARMAX PHARMA LIMITED
Regd. Off. & Factory : Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot-360 311,
Gujarat, INDIA. Tel.: Fac.+91-2827-270534 - 35 - 36 e-mail : info@parmaxpharma.com CIN : L24231GJ1994PLC023504
Correspondence Add.: A/1102, Bilipatra Apts., B/h. Balaji Hall, Nr. Dholakiya School, Off. 150 Ft. Ring Road, Nana Mauva, Rajkot - 360 004, Gujarat (INDIA)